###### Strengths and limitations of this study

-   This is a cross-sectional population-based (13 473 subjects) investigation of the risk factors for diabetic retinopathy (DR).

-   The study was performed in eight hospitals from six different provinces in mainland China, and participants were from hospitals and communities that included rural and urban regions.

-   We separately analysed the risk factors for DR and sight-threatening diabetic retinopathy (STDR), both of which have implications for clinical practice.

-   Owing to the multicentre design, some information was not comprehensively collected, which resulted in an imperfect risk factor analysis.

-   The sampling method of this study was not stratified, which might result in a lack of representativeness.

Introduction {#s1}
============

Diabetes mellitus (DM) is a metabolic syndrome with an increasing prevalence and high mortality rate.[@R1] Diabetic retinopathy (DR) is a common ocular complication of DM and is considered to be one of the leading causes of vision loss and vision impairment in adults.[@R2] With the progression of DR, the quality of life of patients decreases, and the financial burden on society increases, both in the DR screening and treatment groups.[@R3]

DR has been considered to be correlated with many other diabetes-related complications, such as nephropathy, peripheral neuropathy, low bone density and cardiovascular events, all of which lower the quality of life and produce a high rate of mortality.[@R5] Therefore, early diagnosis and proper management of DR would be of great significance.

Many epidemiological studies on DR, either cross-sectional studies[@R9] or cohort studies,[@R19] have been conducted worldwide, exploring the risk factors that were associated with the disease and aiming at the prevention and management of this disease. Older female patients with a longer disease duration were known to be at greater risk for DR and DR progression. Furthermore, having renal complications of diabetes, poor glycaemic control, high lipid levels or hypertension have also already been reported to be risk factors of DR, with an impact on DR progression.[@R9] These factors have been evaluated using the Early Treatment of Diabetic Retinopathy Study classification.[@R27] Of these reported risk factors, the duration of diabetes, hyperglycaemia and hypertension were considered to be the most important risk factors for progression of vision loss.[@R29] However, DR and the risk factors of DR have typically gained little attention, and the compliance with eye screenings is often poor.[@R30] More studies and an improved awareness of the risk factors are therefore required.

In China, a few DR screening studies have been conducted, but most have been completed only in a limited area.[@R21] Therefore, a cross-sectional investigation in six provinces (including the northern and southern parts of China) was conducted. The prevalence of DR and its basic epidemiological characteristics have been reported in a previously published article.[@R31] In this study, we sought to explore the risk factors associated with DR and STDR in mainland China.

Methods {#s2}
=======

Research design {#s2a}
---------------

The Lifeline Express Diabetic Retinopathy Screening Program was conducted nationwide, and it involved a cross-sectional investigation in eight hospitals from six different provinces (Shandong, Henan, Inner Mongolia, Jilin, Guangxi and Guangdong Provinces). Subjects were recruited from hospitals and local communities (1/3 from hospital patients, 1/3 from city residents and the other 1/3 from rural residents) between April 2014 and October 2015. The study protocol was approved by the Peking University Third Hospital Ethics Committee, and written informed consent was obtained for each subject. The study was performed in accordance with the Declaration of Helsinki.

In the hospital, subjects were diagnosed with DM by qualified physicians and transferred to eight screening clinics. In the community, subjects were recruited by advertisement, and medical records of a DM diagnosis were required when they visited the screening clinics. Of all the screening clinics, three were in the south and five were in the north of China. All subjects received a digital, colourful and non-stereoscopic retinography, which was taken by a non-mydriatic auto fundus camera. The photograph included two fields for each eye: one centred at the optic disc and the other centred at the macula.

DR/STDR diagnosis and grading {#s2b}
-----------------------------

DR was graded by trained and certified optometrists and ophthalmologists at the Lifeline Express Diabetic Retinopathy Central Assurance Centre. All of the graders underwent periodic tests to ensure the accuracy of their grading. Retinopathy was graded according to fundus photographs of two eyes into no DR (R0) and DR (other stages), and DR was also graded as none sight-threatening diabetic retinopathy (non-STDR) or sight-threatening diabetic retinopathy (STDR) according to the UK guidelines.[@R32] Non-STDR was recognised as R0 and R1, while STDR was identified as present if any features of maculopathy (M1), preproliferative diabetic retinopathy (R2) or proliferative diabetic retinopathy (R3) were found. If the fundus photographs were ungradable because of missing data or non-diagnostic images due to cataracts or vitreous opacities, the patients were excluded from the risk factor analysis. If the photograph of one eye was unrecognised, the final diagnosis was determined by the only remaining photograph. In this condition, if the remaining photograph was graded R0, patients were excluded because of a lack of evidence. If the remaining photograph was graded R1, patients were diagnosed as DR and excluded from the STDR analysis, while if it was graded as M1, R2 or R3, patients were diagnosed as DR and STDR.

Information collection {#s2c}
----------------------

At the time of the clinical visit, the gender, age, diagnosis age, diabetes duration (calculated from the age and onset age), diabetes type (as evaluated by physicians in screening clinics), body mass index (BMI; calculated from the measured height and weight), waist--hip ratio (WHR; calculated from the measured waistline and hipline) and type of treatment were recorded. Systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), postprandial blood glucose (PBG) 2 hours after eating 75 mg glucose and glycosylated haemoglobin (HbA1c) were measured at the screening clinics, and blood samples after fasting for 8 hours were collected for cholesterol, triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), blood urea nitrogen (BUN) and serum creatinine (Cr) measurements. Gender, age, diagnosis age, diabetes duration, blood pressure (BP), FBG and HbA1c were collected for each patient, while other information was limited to only part of the subjects because of the environment and devices.

Statistical analysis {#s2d}
--------------------

Statistical analyses were performed using SPSS V.18.0. The independent t-test was used to compare continuous variables, and the χ^2^ test was used to compare discontinuous variables among the groups. Owing to the limited number of patients with type 1 and gestational diabetes, we analysed the data from patients with type 2 diabetes only.

We first conducted a four-step analysis of the relationship between the risk factors and DR. In the first step, the mean values and the median values of the main variables were calculated. In the second step, univariate analyses of the associations between the existence of DR and the risk factors were completed. In this step, several continuous variables, including age, diabetes duration, BP, BMI and WHR, were also transferred into categorical variables, to explore their detailed relationship with DR. Age was divided into groups with 10-year intervals, and diabetes duration was divided into groups with 5-year intervals. BP values were catalogues as normal BP, level 1 hypertension, level 2 hypertension and severe hypertension.[@R33] BMI was divided into underweight (\<18.5), normal weight (≥18.5 and \<24), overweight (≥24 and \<28) and obese (≥28) categories. WHR was divided into normal WHR (male ≤0.90 and female ≤0. 85) and abdominal obesity (male 0.90 and female ≤0. 85) and was also divided into male and female groups. In the third step, multicollinearity diagnosis was performed, and a variance inflation factor \>10 was thought to have a high collinearity.[@R34] Furthermore, variables with high a collinearity were evaluated, and the variable that was most relevant to the research purpose was determined by two researchers (JY and YL). In the fourth step, binary logistic regression analyses were carried out, taking the existence of DR as the dependent variable and all risk factors, which were significantly associated with the existence of DR in the former step or considered to be important risk factors based on existing studies, as independent variables. Owing to limitations in the information collection, we separately analysed the eight risk factors that were completely collected in each screening clinic (eight-factor analysis) and all risk factors (all-factor analysis); furthermore, the differences between the two analyses were discussed.

Then, the relationship between the risk factors and STDR was also conducted in the aforementioned way. ORs and 95% CIs were calculated. An α level of 0.05 was adopted as the significance level.

At last, nomograms for DR and STDR risk factors were developed, and significant risk factors in former binary logistic regression were regarded as predictors. Interpretation of the nomogram in the prediction of DR has been reported in former studies,[@R35] which included two major parts. In the first part, the exact values of each predictor were vertically linked to a certain point (the first row of the nomogram), and the total points of each predictor were calculated. In the second part, the total points were linked to a specific risk incidence of DR and STDR (the last row of the nomogram), which has implications for clinical practice.

Results {#s2e}
-------

From April 2014 to October 2015, 13 473 patients with DM from six provinces were enrolled in the study. A percentage of 45.9 patients were from the southern provinces (6180/13 473) and 54.1% were from the northern provinces (7293/13 473). Of all the patients, 13 304 patients were diagnosed with type 2 diabetes, 96 were diagnosed with type 1 diabetes and 73 were diagnosed with gestational diabetes. Patients were divided into a no DR and a DR group and a non-STDR and a STDR group, according to the fundus photograph grading. Five hundred and seventy-one patients were excluded from the DR risk factor analysis, and 683 patients were excluded from the STDR risk factor analysis because of the diagnostic rules mentioned above. Finally, 12 733 patients were included in the DR risk factor analysis, and 12 621 patients were included in the STDR risk factor analysis (shown in [figure 1](#F1){ref-type="fig"}).

![Flow diagram of the data processing. DR, diabetic retinopathy; STDR, sight-threatening diabetic retinopathy.](bmjopen-2017-016280f01){#F1}

First, analyses of the DR risk factors were performed, and the basic characteristics of all risk factors are shown in [table 1](#T1){ref-type="table"}. The results of the univariate analyses indicated that the age, diagnosis age, diabetes duration, SBP, DBP, waistline, hipline, WHR, medicine type (oral medication or insulin injection), FBG, PBG, HbA1c, BUN, and LDL were statistically significantly different between the groups (p\<0.05), and no significant difference was found in the gender, BMI, Cr, cholesterol, triglyceride and HDL (p\>0.05).

###### 

Univariate analysis of DR risk factors (n=12 733)

  ------------------------------------------------------------------------------------------------------------------------
  Variable                        n      No DR\          n      DR\             p                 OR      95% CI
                                         (n=8772)               (n=3961)                                  
  ------------------------------- ------ --------------- ------ --------------- ----------------- ------- ----------------
  Male gender, n (%)              8772   3985 (45.4)     3961   1851 (46.7)     0.172                     

  Age, years (SD)                 8770   63.0 (10.3)     3959   61.0 (9.8)      **\<0.001**               

   \<30, %                        11     30.6            25     69.4                                      

   30--40, % (vs \<30)            143    66.8            71     33.2            0.757             1.128   0.526 to 2.423

   40--50, % (vs 30--40)          733    64.2            408    35.8            0.469             1.121   0.823 to 1.527

   50--60, % (vs 40--50)          2138   63.2            1243   36.8            0.542             1.004   0.908 to 1.201

   60--70, % (vs 50--60)          3443   69.7            1494   30.3            **\<0.001**       0.746   0.680 to 0.819

   \>70, % (vs 60--70)            2217   76.0            700    24.0            **\<0.001**       0.728   0.655 to 0.808

  Diagnosis age, years (SD)       8770   56.3 (10.2)     3959   50.8 (10.3)     **\<0.001**               

  Diabetes duration, years (SD)   8772   6.7 (5.9)       3961   10.2 (6.8)      **\<0.001**               

   \<5, %                         4692   80.0            1174   20.0                                      

   5--10, % (vs \<5)              2314   65.7            1208   34.3            **\<0.001**       2.086   1.898 to 2.293

   10--15, % (vs 5--10)           1032   57.6            761    42.4            **\<0.001**       1.413   1.257 to 1.587

   15--20, % (vs 10--15)          521    48.2            560    51.8            **\<0.001**       1.458   1.252 to 1.696

   \>20, % (vs 15--20)            213    45.2            258    54.8            0.281             1.127   0.907 to 1.400

  BMI (SD)                        6000   24.7 (3.5)      2854   24.9 (3.9)      0.116                     

   Underweight, %                 97     64.7            53     35.3                                      

   Normal weight, %\              3348   68.5            1543   31.5            0.326             0.843   0.600 to 1.185
   (vs underweight)                                                                                       

   Overweight, %\                 2175   67.6            1043   32.4            0.414             1.041   0.946 to 1.145
   (vs normal weight)                                                                                     

   Obese, %\                      380    63.9            215    36.1            0.076             1.180   0.983 to 1.417
   (vs overweight)                                                                                        

  SBP, mm Hg (SD)                 8762   133.3 (16.5)    3952   137.0 (17.9)    **\<0.001**               

  DBP, mm Hg (SD)                 8762   79.6 (9.9)      3952   80.8 (10.8)     **\<0.001**               

   Normal BP, %                   5084   72.3            1950   27.7                                      

   BP level 1, %\                 2840   66.7            1420   33.3            ****\<0.001****   1.303   1.200 to 1.414
   (vs normal)                                                                                            

   BP level 2, %\                 665    59.3            456    40.7            **\<0.001**       1.371   1.198 to 1.569
   (vs level 1)                                                                                           

   BP level 3, %\                 173    57.9            126    42.1            0.648             1.062   0.820 to 1.376
   (vs level 2)                                                                                           

  Waistline, cm (SD)              5719   89.3 (10.1)     2735   90.3 (10.6)     ****\<0.001****           

  Hipline, cm (SD)                5719   96.6 (9.7)      2735   97.1 (9.5)      **0.028**                 

  WHR (SD)                        5719   0.926 (0.074)   2735   0.930 (0.069)   **0.007**                 

  Abdominal obesity, n (%)               4677 (81.8)            2267 (82.9)     0.213             1.079   0.957 to 1.217

   Female (SD)                    3152   0.915 (0.076)   1501   0.923 (0.072)   **0.002**                 

   Male (SD)                      2567   0.94 (0.070)    1234   0.94 (0.064)    0.674                     

  Medicine                        5793                   2797                   **\<0.001**               

   No medicine, %                 660    87.0            99     13.0                                      

   Oral medicine, %\              3296   73.2            1208   26.8            **\<0.001**       5.407   4.331 to 6.752
   (vs no medicine)                                                                                       

   Insulin, %\                    1837   55.2            1490   44.8            **\<0.001**       2.213   2.013 to 2.434
   (vs oral medicine)                                                                                     

  FBG, mmol/L (SD)                7547   7.8 (2.4)       3517   8.7 (3.0)       **\<0.001**               

  PBG, mmol/L (SD)                4780   10.7 (3.3)      2095   11.8 (3.5)      **\<0.001**               

  HbA1c, % (SD)                   7762   7.16 (1.65)     3146   7.82 (1.90)     **\<0.001**               

  BUN, mmol/L (SD)                6357   5.79 (8.19)     2633   6.33 (10.51)    **0.01**                  

  Cr, μmol/L (SD)                 6320   76.5 (112.7)    2615   78.8 (39.2)     0.328                     

  Cholesterol, mmol/L (SD)        6418   5.04 (2.69)     2651   5.06 (1.31)     0.752                     

  Triglyceride, mmol/L (SD)       6382   1.87 (1.22)     2635   1.89 (1.26)     0.456                     

  HDL, mmol/L (SD)                6392   1.37 (0.56)     2642   1.38 (0.57)     0.481                     

  LDL, mmol/L (SD)                6399   2.72 (1.00)     2643   2.83 (1.00)     **\<0.001**               
  ------------------------------------------------------------------------------------------------------------------------

Continuous variables were reported as mean value and SD, and categorical variables were reported as percentage, OR and 95% CI.  p\<0.05 was considered statistically significant and marked in bold.

BMI, body mass index; BP, blood glucose; BUN, blood urea nitrogen; Cr, creatinine; DBP, diastolic blood pressure; DR, diabetic retinopathy; FBG, fasting blood glucose;  HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; n, number; PBG, postprandial blood glucose; SBP, systolic blood pressure; WHR, waist--hip ratio.

Furthermore, our categorical analyses showed that patients were getting less likely to suffer from DR every 10 years after 60 years of age, while no difference was found before age 60. The incidence of DR increased significantly for every 5 years of diabetes duration but stopped increasing after 20 years of diabetes duration. The results of the BP analysis indicated that diabetes incidence increased with increases in the BP, although diabetes incidence did not differ between level 3 BP and level 2 BP. Females had a higher WHR in DR, while males did not, and the condition of abdominal obesity did not influence the incidence of DR.

Then, multivariate analyses were performed. Multicollinearity diagnosis was performed in both the eight-factor analysis and all-factor analysis. The results excluded the diagnosis age (highly correlated to the age and DR duration) in the eight-factor analysis and excluded the diagnosis age (highly correlated to age and DR duration), waistline and hipline (both of which were highly correlated to WHR) in the all-factor analysis because of the high collinearity. Multiple logistic regression analyses were carried out, and the results are shown with the STDR analysis. The results of eight-factor analysis (with the diagnosis age excluded) showed that younger age, longer diabetes duration, higher SBP, higher FBG and higher HbA1c were independent risk factors for DR (p\<0.05), and sex and DBP were not significantly associated with DR (p\>0.05). A multiple logistic regression of the all-factor analysis (with diagnosis age, waistline, and hipline excluded) was also conducted, and the results showed that younger age, longer diabetes duration, higher SBP, HbA1c, PBG, oral medicine, insulin use, higher triglyceride and higher LDL were the independent risk factors for DR (p\<0.05), while sex, DBP, BMI, FBG, WHR, BUN, Cr, cholesterol and HDL were not associated with DR (p\>0.05).

After the DR risk factors analyses, analyses of the STDR risk factors were conducted, and characteristics of the risk factors are shown in [table 2](#T2){ref-type="table"}. Age, diagnosis age, diabetes duration, SBP, DBP, HbA1c, FBG, PBG, waistline, WHR, medicine, Cr and LDL showed statistically significant differences between groups (p\<0.05), while gender, BMI, hipline, BUN, cholesterol, triglyceride and HDL were not significantly different. After a multicollinearity diagnosis, the diagnosis age was excluded in the eight-factor analysis. The diagnosis age, waistline and hipline were excluded in the all-factor analysis. The results of multiple logistic regressions of STDR analyses (together with DR analyses) are shown in [table 3](#T3){ref-type="table"}. The results of the eight-factor analysis (with the diagnosis age dropped) showed that younger age, longer diabetes duration, higher SBP, DBP, FBG and HbA1c were independent risk factors for STDR (p\<0.05), and sex was not significantly associated with STDR (p\>0.05). The results of the all-factor analysis indicated that a younger age, longer diabetes duration, higher SBP, higher FBG, oral medicine use and insulin use were regarded as independent risk factors for STDR (p\<0.05), while other risk factors showed no significant differences (p\>0.05).

###### 

Univariate analysis of STDR risk factors (n=12 621)

  ----------------------------------------------------------------------------------------------------------------------
  Variable                        n        None-STDR\      n      STDR\           p             OR      95% CI
                                           (n=10 875)             (n=1746)                              
  ------------------------------- -------- --------------- ------ --------------- ------------- ------- ----------------
  Male gender, n (%)              10 875   4985 (45.8)     1746   799 (45.8)      0.952                 

  Age, years (SD)                 10 873   62.7 (10.2)     1745   60.4 (9.7)      **\<0.001**           

   \<30, %                        32       88.9            4      11.1                                  

   30--40, % (vs \<30)            181      85.0            32     15.0            0.757         1.128   0.526 to 2.423

   40--50, % (vs 30--40)          927      81.9            205    18.1            0.469         1.121   0.823 to 1.527

   50--60, % (vs 40--50)          2785     82.9            576    17.1            0.542         1.004   0.908 to 1.201

   60--70, % (vs 50--60)          4253     86.9            643    13.1            **\<0.001**   0.746   0.680 to 0.819

  \>70, % (vs 60--70)             2160     88.9            270    11.1            **\<0.001**   0.728   0.655 to 0.808

  Diagnosis age, years (SD)       10 873   55.4 (10.4)     1745   49.4 (10.4)     **\<0.001**           

  Diabetes duration, years (SD)   10 875   7.2 (6.2)       1746   11.0 (6.8)      **\<0.001**           

   \<5, %                         4692     80.0            1174   20.0                                  

   5--10, % (vs \<5)              2314     65.7            1208   34.3            **\<0.001**   2.086   1.898 to 2.293

   10--15, % (vs 5--10)           1032     57.6            761    42.4            **\<0.001**   1.413   1.257 to 1.587

   15--20, % (vs 10--15)          521      48.2            560    51.8            **\<0.001**   1.458   1.252 to 1.696

   \>20, % (vs 15--20)            213      45.2            258    54.8            0.281         1.127   0.907 to 1.400

  BMI (SD)                        7518     24.8 (3.6)      1256   24.8 (3.9)      0.738                 

   Underweight                    120      81.1            28     18.9                                  

   Normal weight, %\              4145     85.5            703    14.5            0.134         0.727   0.478 to 1.105
   (vs underweight)                                                                                     

   Overweight, %\                 2759     86.6            428    13.4            0.177         0.915   0.804 to 1.041
   (vs normal weight)                                                                                   

   Obese, %\                      494      83.6            97     16.4            0.054         1.266   0.995 to 1.610
   (vs overweight)                                                                                      

  SBP, mm Hg (SD)                 10 863   133.8 (16.7)    1741   138.1 (18.7)    **\<0.001**           

  DBP, mm Hg (SD)                 10 863   79.8 (10.0)     1741   81.0 (11.4)     **\<0.001**           

  Normal BP, %                    6164     88.2            826    11.8                                  

   BP level 1, %\                 3584     85.0            630    15.0            **\<0.001**   1.312   1.173 to 1.467
   (vs normal BP)                                                                                       

   BP level 2, %\                 892      80.5            216    19.5            **\<0.001**   1.378   1.161 to 1.635
   (vs BP level 1)                                                                                      

   BP level 3, %\                 223      76.4            69     23.6            0.118         1.278   0.939 to 1.739
   (vs BP level 2)                                                                                      

  Waistline, cm (SD)              7176     89.4 (10.1)     1200   90.7 (10.8)     **\<0.001**           

  Hipline, cm (SD)                7176     96.7 (9.6)      1200   97.2 (10.1)     0.120                 

  WHR (SD)                        7176     0.926 (0.073)   1200   0.934 (0.071)   **0.001**             

   Abdominal obesity, n (%)                5872 (81.8)            1004 (83.7)     0.124         1.113   0.970 to 1.276

  Female (SD)                     3947     0.92 (0.075)    666    0.93 (0.074)    **\<0.001**           

  Male (SD)                       3229     0.94 (0.069)    534    0.94 (0.065)    0.634                 

  Medicine                        7304                     1218                   **\<0.001**           

   No medicine, %                 727      93.7            49     6.3                                   

   Oral medicine, %\              4008     89.6            465    10.4            **\<0.001**   2.908   1.982 to 4.267
   (vs no medicine)                                                                                     

   Insulin, %\                    2569     78.0            724    22.0            **\<0.001**   2.429   2.140 to 2.757
   (vs oral medicine)                                                                                   

  FBG, mmol/L (SD)                9451     8.0 (2.5)       1521   8.9 (3.1)       **\<0.001**           

  PBG, mmol/L (SD)                5964     10.9 (3.3)      886    11.9 (3.6)      **\<0.001**           

  HbA1c, % (SD)                   9548     7.25 (1.70)     1280   8.05 (1.97)     **\<0.001**           

  BUN, mmol/L (SD)                7855     5.89 (9.38)     1072   6.38 (4.99)     0.092                 

  Cr, μmol/L (SD)                 7812     76.2 (102.1)    1060   84.2 (52.3)     **0.012**             

  Cholesterol, mmol/L (SD)        7927     5.05 (2.48)     1079   5.06 (1.29)     0.904                 

  Triglyceride, mmol/L (SD)       7884     1.87 (1.22)     1072   1.94 (1.29)     0.072                 

  HDL, mmol/L (SD)                7897     1.37 (0.56)     1074   1.38 (0.54)     0.755                 

  LDL, mmol/L (SD)                7907     2.74 (0.99)     1072   2.82 (1.06)     **0.015**             
  ----------------------------------------------------------------------------------------------------------------------

p\<0.05 was considered statistically significant and marked in bold.

BMI, body mass index; BP, blood glucose; BUN, blood urea nitrogen; Cr, creatinine; DBP, diastolic blood pressure; FBG, fasting blood glucose;  HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; n, number; PBG, postprandial blood glucose; SBP, systolic blood pressure; STDR, sight-threatening diabetic retinopathy; WHR, waist--hip ratio.

###### 

Logistic regression of DR and STDR risk factors (both in eight-factor analysis and all-factor analysis)

  Variable                      OR      95% CI           p             OR      95% CI           p             OR      95% CI           p             OR      95% CI            p
  ----------------------------- ------- ---------------- ------------- ------- ---------------- ------------- ------- ---------------- ------------- ------- ----------------- -------------
  Sex (women vs men)            1.026   0.932 to 1.130   0.169         1.052   0.913 to 1.213   0.489         0.979   0.855 to 1.120   0.753         1.176   0.960 to 1.442    0.118
  Age                           0.966   0.961 to 0.971   **\<0.001**   0.968   0.961 to 0.976   **\<0.001**   0.961   0.954 to 0.968   **\<0.001**   0.961   0.950 to 0.972    **\<0.001**
  Diabetes duration             1.102   1.093 to 1.111   **\<0.001**   1.071   1.059 to 1.084   **\<0.001**   1.102   1.091 to 1.113   **\<0.001**   1.077   1.061 to 1.094    **\<0.001**
  SBP                           1.015   1.011 to 1.018   **\<0.001**   1.016   1.010 to 1.021   **\<0.001**   1.017   1.011 to 1.021   **\<0.001**   1.017   1.010 to 1.024    **\<0.001**
  DBP                           0.995   0.989 to 1.001   0.083         0.994   0.986 to 1.002   0.152         0.987   0.980 to 0.995   **0.002**     0.990   0.979 to 1.002    0.095
  FBG                           1.040   1.019 to 1.062   **\<0.001**   1.008   0.972 to 1.046   0.666         1.043   1.016 to 1.071   **0.002**     1.076   1.028 to 1.127    **0.002**
  HbA1c                         1.164   1.128 to 1.201   **\<0.001**   1.102   1.051 to 1.156   **\<0.001**   1.168   1.172 to 1.250   **\<0.001**   1.060   0.994 to 1.130    0.077
  PBG                                                                  1.039   1.014 to 1.065   **0.003**                                            1.013   0.979 to 1.048    0.473
  BMI                                                                  0.991   0.972 to 1.012   0.406                                                0.976   0.948 to 1.005    0.109
  WHR                                                                  1.527   0.591 to 3.947   0.382                                                3.314   0.927 to 11.842   0.065
  Medicine                                                                                                                                                                     
   Oral versuss no medicine                                            2.158   1.517 to 3.069   **\<0.001**                                          3.737   1.721 to 8.113    **0.001**
   Insulin versus no medicine                                          3.535   2.455 to 5.089   **\<0.001**                                          6.856   3.141 to 14.966   **\<0.001**
  BUN                                                                  1.004   0.997 to 1.011   0.238                                                1.002   0.994 to 1.010    0.598
  Cr                                                                   1.000   1.000 to 1.001   0.745                                                1.000   1.000 to 1.001    0.121
  Cholesterol                                                          0.999   0.955 to 1.044   0.948                                                0.995   0.924 to 1.071    0.890
  Triglyceride                                                         0.924   0.873 to 0.979   **0.007**                                            0.950   0.878 to 1.028    0.200
  HDL                                                                  1.030   0.901 to 1.176   0.668                                                0.970   0.789 to 1.193    0.776
  LDL                                                                  1.099   1.017 to 1.187   **0.017**                                            1.093   0.978 to 1.221    0.118

p\<0.05 was considered statistically significant and marked in bold.

BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; DBP, diastolic blood pressure; DR, diabetic retinopathy; FBG, fasting blood glucose;  HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; n, number; PBG, postprandial blood glucose; SBP, systolic blood pressure; STDR, sight-threatening diabetic retinopathy; WHR, waist--hip ratio.

Furthermore, we subcategorised the non-STDR group into the non-DR and DR but not STDR groups, and the risk factors between the DR but not STDR group and the non-DR, STDR or DR group. The results showed that independent risk factors for DR but not STDR compared with non-DR were exactly the same as for DR/no DR. However, the risk factors of the STDR compared with DR but not STDR analysis showed two new independent risk factors in addition to those for STDR/non-STDR, which were male sex and Cr.

Finally, we developed a nomogram to simplify the presentation and understanding of our results ([figure 2](#F2){ref-type="fig"}).

![Nomograms for DR (A) and STDR (B) risk factors. Risk factors were chosen based on results of logistic regression analysis. Each risk factor of the patient was assessed on basis of the nomogram and got a point by vertically corresponding to the first line. Aggregated points of each risk factor corresponded to a particular occurrence probability of DR or STDR in the last line. DR, diabetic retinopathy; DM, diabetes mellitus; FBG, fasting blood -glucose; HbA1c, glycosylated haemoglobin; LDL, low-density lipoprotein; PBG, postprandial blood glucose; SBP, systolic blood pressure; STDR, sight-threatening diabetic retinopathy.](bmjopen-2017-016280f02){#F2}

Discussion {#s3}
==========

Based on the results of our study, we tried to find a reasonable explanation and an internal relationship between DR, STDR and risk factors.

First, focusing on the univariate analysis, 14 out of 20 risk factors were found to be significantly different between the non-DR and DR groups, and 13 out of 20 factors were found to be different between the non-STDR and STDR groups. Basically, all risk factors were divided into non-modifiable and modifiable risk factors. Non-modifiable factors included gender, age, diagnosis age and diabetes duration. In both the non-DR/DR and the non-STDR/STDR analyses, gender showed no significant differences. This was also reported in several previous studies,[@R10] while the results of some studies remained controversial.[@R11] Significantly younger age was observed in the DR and STDR groups, and a longer duration of diabetes was also found in the DR and STDR groups. Longer duration may represent a longer period of retinal toxicity induced by high glucose levels, which is believed to be associated with both vascular and neural death in the retina.[@R36] The existing studies show an older or much younger age in the DR patients than in the non-DR patients.[@R26] In our study, an older age seemed to be a protective variable for DR but was instead found to be a variable for STDR, especially in patients with DM older than 60. This means that even though older age was associated with a lower incidence of DR, it is associated with a greater threat to vision. We thought that this phenomenon might be explained by the higher mortality risk in older DR populations. However, as DR was correlated with severe general diseases,[@R37] this result might be related to survival bias. However, older age also implied a longer suffering of hyperglycaemia, which might be more vision threatening. Furthermore, we explored the relationship between age and HbA1c, diabetes duration and the therapeutic regimen. The results indicated that with increasing age, the diabetes duration increased, while the HbA1c and use of insulin decreased. This implied that although the duration of diabetes increased, older people had a better glucose management and required milder medicine. In this way, age was determined to be a protective factor.

Modifiable risk factors included the obesity index, BP, medicine, blood glucose, renal function and blood lipid levels. Both DR and STDR showed a significantly higher WHR, BP, blood glucose level, LDL and a higher incidence of insulin use than the non-DR and non-STDR groups. BUN was only significantly higher in the DR group than the non-DR group, meanwhile Cr was only significantly higher in the STDR than in the non-STDR group. WHR was thought to be associated with DM[@R38] and was also thought to be a risk factor for severe DR in women.[@R39] Our study showed similar results in the univariate analysis. High BP indicated a significantly higher incidence of DR and STDR, while the effects did not increase after a certain level. Blood glucose and LDL were significantly higher in the DR and STDR groups than in the non-DR and non-STDR groups, while the cholesterol level showed no significant difference, indicating that the DR and STDR groups had poor management of blood glucose and LDL. BUN and Cr were both common variables that reflected renal function, and our study indicated that DR and STDR showed a higher level of renal injury than the non-DR and non-STDR groups. The application of oral medicine or insulin was also reported to be a risk factor in the former studies, perhaps because of the severity of the disease condition.[@R11]

Second, the results of multiple logistic regression analyses showed that independent risk factors of DR and STDR were similar in the eight-factor analysis (with the diagnosis age excluded) and were different in the all-factor analysis (with diagnosis age, waistline and hipline excluded). In the all-factor analysis, younger age, diabetes duration and SBP were found to be independent risk factors for both DR and STDR, while PBG, HbA1c, triglyceride and LDL were found to be independent risk factors for DR only, and FBG was found to be an independent risk factor for STDR only. Age, diabetes duration and SBP were reported to be independent risk factors for DR or DR progression,[@R10] while differences in the blood glucose were harder to explain. HbA1c has been reported to be an independent risk factor in the development and progression of DR in earlier studies,[@R18] but there is little evidence on the role of PBG in DR progression. HbA1c has long been considered to represent the management condition of blood glucose, and bad glucose management is known to contribute to the occurrence and progression of DR.[@R9] PBG was reported to be abnormal in 31% of patients with DM whose FBG was normal,[@R40] so it was considered to be an important diagnostic factor for DM. PBG was shown to be more valuable in the prediction of ischaemic and haemorrhagic stroke and cardiovascular disease mortality, while FBG showed only weak predictive power.[@R41] Therefore, we thought that it was reasonable that PBG was a risk factor for severe complications of DM, such as DR. One possible mechanism of PBG in the progression of DR might be that PBG reflects the capacity of insulin secretion, the peak of which was shown to be delayed in type 2 DM[@R43]. High levels of PBG indicate that insulin secretion is relatively insufficient, which might result in a blood glucose fluctuation after food intake and subsequent harm to the targeted organs. Our study first found that FBG was an independent risk factor for STDR, although we note that the OR was only 1.043 for a 1 unit increase in FBG and thus has a limited power to predict the incidence of STDR. No existing studies previously showed that FBG was an independent risk factor for DR, which might be caused by a higher predictive value of HbA1c in these studies. Determining a possible mechanism of FBG for STDR required further studies. LDL and triglyceride levels were also independent risk factors for DR, which indicated that the management of blood lipids is very important for DR prevention but was of limited relevance for STDR compared with the other risk factors.

This study explored the risk factors of DR and STDR, which provided some insights for the DR progression in Chinese population, and our findings could be applied nationwide for further DR management. Our study also had some limitations. First, owing to the limitations of the device and screening environment, several variables were incomplete. If we meant to analyse all variables in this study, considerable data would be abandoned, and the results of multivariate regression might be influenced. Second, although we tried to balance patients from north and south and from urban and rural areas, the patients enrolled in the final all-factor logistic regression were not fully balanced because of the exclusion of missing data. Third, patients and screening clinics were not collected via stratified sampling and therefore were not fully representative of patients in mainland China. Fourth, our study design was cross-sectional. Compared with cohort studies, cross-sectional studies provide weaker evidence, and the results must be carefully explained. Fifth, the risk factors explored in this study had been reported in previous studies, and further studies should thus include more risk factors. More cohort studies focusing on several areas of China will therefore be required to expand on these results.

Conclusions {#s4}
===========

Our study demonstrated that age, diabetes duration and SBP were independent risk factors for both DR and STDR. PBG, HbA1c, triglyceride and LDL were independent risk factors for DR only, and FBG was an independent risk factor for STDR only. These results are similar to the results of existing studies and may provide some evidence for the clinical prevention of DR and STDR, especially as FBG, PBG, and HbA1c were all important predictors for the occurrence or progression of DR, requiring stricter glucose control. More DR screening and information collection are required, which may decrease the incidence of DR and improve clinical results.
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